# EDGAR Filing Document

**Accession Number:** 0001625297
**File Stem:** 0001625297-26-000024
**Filing Date:** 2026-5
**Character Count:** 8049
**Document Hash:** 0056161eadccd522b0caadce90e1685c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001625297-26-000024.hdr.sgml**: 20260515

**ACCESSION NUMBER**: 0001625297-26-000024

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20260513

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20260515

**DATE AS OF CHANGE**: 20260515

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Indivior Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001625297
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 412520873
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37835
- **FILM NUMBER:** 26986716

**BUSINESS ADDRESS:**
- **STREET 1:** 10710 MIDLOTHIAN TURNPIKE
- **STREET 2:** SUITE 125
- **CITY:** NORTH CHESTERFIELD
- **STATE:** VA
- **ZIP:** 23235
- **BUSINESS PHONE:** 804-379-1090

**MAIL ADDRESS:**
- **STREET 1:** 10710 MIDLOTHIAN TURNPIKE
- **STREET 2:** SUITE 125
- **CITY:** NORTH CHESTERFIELD
- **STATE:** VA
- **ZIP:** 23235

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INDIVIOR PLC
- **DATE OF NAME CHANGE:** 20141114

?xml version='1.0' encoding='ASCII'? indv-20260513

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): May 13, 2026

**INDIVIOR PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

Delaware 001-37835 41-2520873 <br> (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

10710 Midlothian Turnpike, Suite 125North Chesterfield, VA 23235 <br> (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: 804-379-1090

not applicable <br> (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common stock, $0.001 par value per share | INDV | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

------

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** 

(b) Effective June 1, 2026, Indivior Pharmaceuticals, Inc. (the "Company" or the "Registrant") will eliminate the position of Chief Scientific Officer. Dr. Christian Heidbreder will continue to report to the CEO in an advisory capacity on special projects through the end of 2026. Dr. Heidbreder's employment will terminate on December 31, 2026, and his termination will be treated as a termination without cause pursuant to the terms of his existing employment agreement with the Company.

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

The Company held a virtual annual meeting of stockholders on May 13, 2026, at 10:00 a.m. Eastern Time. A total of 121,922,058 shares of common stock of the Company were entitled to vote as of March 18, 2026, the record date for the Annual Meeting, of which 100,407, 7225 were present in person or by proxy at the Annual Meeting. Details of each matter voted upon were described in a definitive proxy statement filed with the U.S. Securities and Exchange Commission on March 27, 2026 (the "Proxy Statement"). The stockholders duly elected each person nominated to serve as a director, and approved each matter presented, by the following votes:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.To elect eight director nominees, each to serve for a one-year term extending until our 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **<u>Nominee</u>** | **<u>Votes For</u>** | **<u>Votes Against</u>** | **<u>Votes Abstained</u>** | **<u>Broker Non-Votes</u>** |
| Dr. David Wheadon | 91378828 | 1534064 | 24804 | 7470026 |
| Joe Ciaffoni | 92834811 | 76839 | 26046 | 7470026 |
| Dr. Keith Humphreys | 92839955 | 72084 | 25657 | 7470026 |
| Tony Kingsley | 92839469 | 72503 | 25724 | 7470026 |
| Daniel Ninivaggi | 87545032 | 5366849 | 25815 | 7470026 |
| Barbara Ryan | 91562195 | 1302383 | 73118 | 7470026 |
| Mark Stejbach | 92838962 | 72847 | 25887 | 7470026 |
| Juliet Thompson | 92136342 | 728040 | 73314 | 7470026 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement (Say-on-Pay):

---

| | | | |
|:---|:---|:---|:---|
| **<u>Votes For</u>** | **<u>Votes Against</u>** | **<u>Votes Abstained</u>** | **<u>Broker Non-Votes</u>** |
| 90,364,566 | 1,324,996 | 1,248,134 | 7,470,026 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of our named executive officers (Say-on-Frequency):

---

| | | | | |
|:---|:---|:---|:---|:---|
| **<u>Votes For 1 Year</u>** | **<u>Votes For 2 Years</u>** | **<u>Votes For 3 Years</u>** | **<u>Votes Abstained</u>** | **<u>Broker Non-Votes</u>** |
| 91,848,954 | 21,701 | 1,032,941 | 34,100 | 7,470,026 |

---

In light of the shareholder vote, and in keeping with the Board's recommendation on Proposal 3, the Company will hold a "say-on-pay" vote annually until the next vote on the frequency of "say-on-pay" votes is required (which will be no later than the 2032 Annual Meeting of Shareholders) or until the Board determines that a different frequency for "say-on-pay" votes is in the best interest of the Corporation and its shareholders.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. To ratify the appointment of PricewaterhouseCoopers LLP US (PwC) as our independent registered public accounting firm for the fiscal year ending December 31, 2026:

---

| | | | |
|:---|:---|:---|:---|
| **<u>Votes For</u>** | **<u>Votes Against</u>** | **<u>Votes Abstained</u>** | **<u>Broker Non-Votes</u>** |
| 99,146,241 | 1,237,984 | 23,497 | 0 |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | | **Indivior Pharmaceuticals, Inc.** |
| &nbsp;&nbsp;Date: May 15, 2026 | By: | /s/ Ryan Preblick |
|  |  | Name: Ryan Preblick |
|  |  | Title: Chief Financial Officer |

---